Brokerages Set Compass Therapeutics, Inc. (NASDAQ:CMPX) Target Price at $12.25

Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) have earned an average recommendation of “Moderate Buy” from the fifteen analysts that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among analysts that have covered the stock in the last year is $12.25.

A number of equities research analysts have commented on CMPX shares. LADENBURG THALM/SH SH assumed coverage on Compass Therapeutics in a research note on Wednesday, July 1st. They issued a “buy” rating and a $5.00 price target for the company. Citizens Jmp restated a “market outperform” rating and set a $10.00 price objective on shares of Compass Therapeutics in a report on Tuesday, April 28th. Raymond James Financial lowered shares of Compass Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Tuesday, April 28th. D. Boral Capital reiterated a “buy” rating and issued a $30.00 target price on shares of Compass Therapeutics in a research note on Monday, April 27th. Finally, Canaccord Genuity Group dropped their target price on shares of Compass Therapeutics from $13.00 to $7.00 and set a “buy” rating on the stock in a research report on Tuesday, April 28th.

Institutional Investors Weigh In On Compass Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the stock. LPL Financial LLC increased its position in shares of Compass Therapeutics by 4.7% in the 4th quarter. LPL Financial LLC now owns 44,470 shares of the company’s stock valued at $239,000 after acquiring an additional 2,000 shares during the period. Victory Capital Management Inc. increased its holdings in Compass Therapeutics by 20.6% in the third quarter. Victory Capital Management Inc. now owns 12,652 shares of the company’s stock valued at $44,000 after buying an additional 2,164 shares in the last quarter. Focus Partners Wealth raised its holdings in Compass Therapeutics by 16.2% in the 3rd quarter. Focus Partners Wealth now owns 15,805 shares of the company’s stock worth $56,000 after purchasing an additional 2,206 shares during the period. Invesco Ltd. lifted its position in shares of Compass Therapeutics by 5.3% during the 4th quarter. Invesco Ltd. now owns 63,901 shares of the company’s stock valued at $343,000 after buying an additional 3,245 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its position in Compass Therapeutics by 1.9% during the third quarter. Dimensional Fund Advisors LP now owns 175,556 shares of the company’s stock worth $619,000 after acquiring an additional 3,329 shares during the period. 68.43% of the stock is currently owned by institutional investors and hedge funds.

Compass Therapeutics Trading Down 2.4%

Shares of CMPX stock opened at $2.07 on Tuesday. Compass Therapeutics has a 12-month low of $1.61 and a 12-month high of $6.88. The business’s fifty day simple moving average is $2.11 and its 200-day simple moving average is $4.10. The company has a market cap of $372.79 million, a PE ratio of -5.05 and a beta of 0.90.

Compass Therapeutics (NASDAQ:CMPX) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($0.10) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.10). On average, equities analysts forecast that Compass Therapeutics will post -0.42 earnings per share for the current year.

About Compass Therapeutics

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.